Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Syed Hissar

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|December 6, 2021
Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment FailureNathella Pavan Kumar, Kadar Moideen, Arul Nancy, et al.
Hepatology International|August 12, 2009
Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patientsK Manohar, P V Suneetha, Sukriti, et al.
BMC Infectious Diseases|December 11, 2019
Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapyNathella Pavan Kumar, Kadar Moideen, Arul Nancy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2022
Heightened Microbial Translocation Is a Prognostic Biomarker of Recurrent TuberculosisNathella Pavan Kumar, Kadar Moideen, Vijay Viswanathan, et al.
Frontiers in Immunology|February 23, 2023
Chitinase and indoleamine 2, 3-dioxygenase are prognostic biomarkers for unfavorable treatment outcomes in pulmonary tuberculosisNathella Pavan Kumar, Arul Nancy, Vijay Viswanathan, et al.
Frontiers in Immunology|September 13, 2024
Cytokine and chemokine profiles in pulmonary tuberculosis with pre-diabetesAnuradha Rajamanickam, Sanaadhan P Kothandaraman, Nathella Pavan Kumar, et al.
Frontiers in Cellular and Infection Microbiology|October 22, 2019
Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial BurdenNathella Pavan Kumar, Kadar Moideen, Arul Nancy, et al.
Journal of Gastroenterology and Hepatology|July 25, 2007
Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experienceAjit Sood, Vandana Midha, Syed Hissar, et al.
Hepatology (Baltimore, Md.)|February 3, 2009
Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infectionNirupma TrehanPati, Robert Geffers, Sukriti, et al.
Pathogens (Basel, Switzerland)|February 26, 2025
Association of Altered Baseline Hematological Parameters with Adverse Tuberculosis Treatment OutcomesArul Nancy Pandiarajan, Nathella Pavan Kumar, Kadar Moideen, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|December 6, 2021
Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment FailureNathella Pavan Kumar, Kadar Moideen, Arul Nancy, et al.
Hepatology International|August 12, 2009
Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patientsK Manohar, P V Suneetha, Sukriti, et al.
BMC Infectious Diseases|December 11, 2019
Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapyNathella Pavan Kumar, Kadar Moideen, Arul Nancy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2022
Heightened Microbial Translocation Is a Prognostic Biomarker of Recurrent TuberculosisNathella Pavan Kumar, Kadar Moideen, Vijay Viswanathan, et al.
Frontiers in Immunology|February 23, 2023
Chitinase and indoleamine 2, 3-dioxygenase are prognostic biomarkers for unfavorable treatment outcomes in pulmonary tuberculosisNathella Pavan Kumar, Arul Nancy, Vijay Viswanathan, et al.
Frontiers in Immunology|September 13, 2024
Cytokine and chemokine profiles in pulmonary tuberculosis with pre-diabetesAnuradha Rajamanickam, Sanaadhan P Kothandaraman, Nathella Pavan Kumar, et al.
Frontiers in Cellular and Infection Microbiology|October 22, 2019
Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial BurdenNathella Pavan Kumar, Kadar Moideen, Arul Nancy, et al.
Journal of Gastroenterology and Hepatology|July 25, 2007
Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experienceAjit Sood, Vandana Midha, Syed Hissar, et al.
Hepatology (Baltimore, Md.)|February 3, 2009
Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infectionNirupma TrehanPati, Robert Geffers, Sukriti, et al.
Pathogens (Basel, Switzerland)|February 26, 2025
Association of Altered Baseline Hematological Parameters with Adverse Tuberculosis Treatment OutcomesArul Nancy Pandiarajan, Nathella Pavan Kumar, Kadar Moideen, et al.
Pageof 7